Cargando…
THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
BACKGROUND: Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of death among women worldwide. Early BC is potentially curable, but the mortality rates still observed among BC patients demonstrate the urgent need of novel and more effective diagnostic and therapeutic opti...
Autores principales: | Apolónio, Joana Dias, Dias, João S., Fernandes, Mónica Teotónio, Komosa, Martin, Lipman, Tatiana, Zhang, Cindy H., Leão, Ricardo, Lee, Donghyun, Nunes, Nuno Miguel, Maia, Ana-Teresa, Morera, José L., Vicioso, Luis, Tabori, Uri, Castelo-Branco, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759897/ https://www.ncbi.nlm.nih.gov/pubmed/36529814 http://dx.doi.org/10.1186/s13148-022-01396-3 |
Ejemplares similares
-
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
por: Leão, Ricardo, et al.
Publicado: (2018) -
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer
por: Leão, Ricardo, et al.
Publicado: (2018) -
Thor, with angels : a play /
por: Fry, Christopher, 1907-2005
Publicado: (1948) -
A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study
por: Castelo-Branco, Pedro, et al.
Publicado: (2016) -
Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers
por: de Almeida, Bernardo P., et al.
Publicado: (2019)